Table 4 Integrin-targeting therapies in clinical trials

Natalizumab biosimilar

NCT04115488

Polpharma Biologics S.A.

Antibody

2019-10-04

α4β1;α4β7

Relapsing-remitting multiple sclerosis

300 mg every 4 weeks

IV

Phase III

Etrolizumab

Ulcerative colitis:

NCT02100696;

NCT02118584;

NCT02136069;

NCT02165215;

NCT02163759;

NCT02171429;

Crohn’s disease:

NCT02394028;

NCT02403323;

Hoffmann-La Roche

Antibody

UC:

2014-04-01

2014-04-21

2014-05-12

2014-06-17

2014-06-16

2014-06-24

CD:

2015-03-20

2015-03-31

α4β7;αEβ7

Ulcerative colitis and Crohn’s disease

Ulcerative colitis: 105 mg Q4W

Crohn’s disease: 210 mg at Weeks 0, 2, 4, 8, and 12 /105 mg Q4W

SC

Phase III

SAN-300

NCT02047604

Bausch Health Americas, Inc.

Antibody

2014-01-28

α1β1

Rheumatoid arthritis

0.5 mg/kg QW

1.0 mg/kg QW

2.0 mg/kg QOW

4.0 mg/kg QOW

4.0 mg/kg QW

SC

Phase II

Abrilumab

NCT01694485;

NCT01696396;

NCT01959165;

AstraZeneca

Antibody

2012-09-27

2012-10-01

2013-10-09

α4β7

Ulcerative colitis

21 mg, 70 mg or 210 mg (on day 1, week 2, week 4, and every 4 weeks thereafter until week 24)

SC

Phase II

Abituzumab

NCT01008475;

NCT01360840;

NCT02745145;

EMD Serono Research & Development Institute, Inc.

Antibody

2009-11-05

2011-05-26

2016-04-20

pan-αv

K-ras wild-type metastatic colorectal cancer;

metastatic castrate-resistant prostate cancer;

systemic sclerosis-associated interstitial lung disease;

K-ras Wild Type Metastatic Colorectal Cancer: 250 mg IV for 1 h Q2W;

Metastatic Castrate-resistant Prostate Cancer (PERSEUS): 750 mg IV for 1 hour Q3W;

Systemic Sclerosis-associated Interstitial Lung Disease:500 mg/1500 mg IV for 1 hour Q4W;

IV

Phase II

Etaracizumab

NCT00192517

Medimmune Llc

Antibody

2005-09-19

αvβ3

Plaque psoriasis

4 mg/kg

SC

Phase II

VPI-2690B

NCT02251067

Vascular Pharmaceuticals, Inc.

Antibody

2014-09-26

αvβ3

Diabetic nephropathy

6 mg,18 mg,48 mg QOW

SC

Phase II

Intetumumab

NCT00246012;

NCT00537381;

Centocor, Inc.

Antibody

2005-10-30

2007-10-01

pan-αv

Melanoma;

metastatic hormone refractory prostate cancer;

Melanoma: 3 mg/kg、5 mg/kg or 10 mg/kg Q3W

Metastatic Hormone Refractory Prostate Cancer: 10 mg/kg QW for initial 6 weeks, then Q3W

IV

Phase II

ASP-5094

NCT03257852

Astellas Pharma Inc

Antibody

2017-08-22

α9β1

Rheumatoid arthritis

Not mentioned

IV

Phase II

Volociximab

NCT00099970;

NCT00100685;

NCT00278187;

NCT00369395;

NCT00401570;

NCT00516841;

Abbott Laoratories/

Facet Biotech

Antibody

2004-12-22

2005-01-05

2006-01-18

2006-08-29

2006-11-20

2007-08-16

α5β1

Non-small cell lung cancer;

pancreatic cancer;

epithelial ovarian cancer or primary peritoneal cancer;

renal cell carcinoma;

melanoma;

Non-Small Cell Lung Cancer: IV over 30 min QOW;

Metastatic Pancreatic Cancer: 10 mg/kg or 15 mg/kg QW or QOW;

Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer: 15 mg/kg QW;

Metastatic Renal Cell Carcinoma : 10 mg/kg QOW /15 mg/kg QW;

Metastatic Melanoma:5 mg/kg QW

IV

Phase II (terminated)

BG-00011

NCT00878761;

NCT01371305;

NCT03573505;

Stromedix, Inc.;

Biogen;

Antibody

2009-04-09

2011-06-10

2018-06-29

αvβ1;αvβ6

Renal transplant patients with biopsy proven interstitial fibrosis and tubular atrophy;

idiopathic pulmonary fibrosis;

Renal Transplant Patients With Biopsy Proven Interstitial Fibrosis and Tubular Atrop: 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg or 1 mg/kg;

Idiopathic Pulmonary Fibrosis: 56 mg QW

SC

Phase II (terminated)

Vatelizumab

NCT01659138;

NCT01861249;

NCT02222948;

NCT02306811;

Sanofi

Antibody

2012-08-07

2013-05-23

2014-08-22

2014-12-03

α2β1

Multiple sclerosis; ulcerative

colitis;

Not mentioned

IV

Phase II (terminated)

ABBV-382

NCT04554966

AbbVie

Antibody

2020-09-18

α4β7

HIV

Not mentioned

IV or SC

Phase I

MINT-1526A

NCT01139723

Genentech, Inc.

Antibody

2010-06-08

α5β1

Solid tumors

Not mentioned

IV

Phase I

OS2966

NCT04608812

OncoSynergy, Inc.

Antibody

2020-10-29

β1

Glioma

Not mentioned

Intratumoural infusion

Phase I

Anti-GPIIb/IIIa chimeric monoclonal antibody F(ab’)2

CXSL0500115

Shanghai Yalian Antibody Pharmaceutical Co., Ltd.

Antibody

2006-03-13

αIIbβ3

Venous thrombosis

Not mentioned

Not mentioned

Phase I

Recombinant anti-CD11a humanized monoclonal antibody

CXSL0500018

Sansheng Guojian Pharmaceutical (Shanghai) Co., Ltd.

Antibody

2005-10-25

LFA-1A

Psoriasis

Not mentioned

Not mentioned

Phase I

Anti-CD8 monoclonal antibody

NCT01048372

CytoDyn, Inc.

Antibody

2010-01-13

LFA-1A

HIV infections

Not mentioned

Not mentioned

Phase I

PF-4605412

NCT00915278

Pfizer

Antibody

2009-06-08

α5β1

Solid tumors

7.5 mg IV for 2 h every 4 or 2 weeks

IV

Phase I (terminated)

Cilengitide

NCT00689221

EMD Serono

Peptide

2008-06-03

αvβ3;αvβ5

Glioblastoma and methylated gene promoter status

2000 mg twice weekly over 1 h

IV

Phase III (terminated)

batifiban

CTR20130809;

CTR20130814;

BIO-THERA

Peptide

2018-05-02

2013-10-23

αIIbβ3

Acute coronary syndrome and thrombotic cardiovascular events

bolus 220ug/kg (0.11 ml/kg) for 1–2 min, IV 2.5ug/kg/min for 24 h

IV

Phase III

MT-1002

NCT04723186

Shaanxi Micot Technology Limited Company

Peptide

2021-01-25

αIIbβ3

Acute coronary syndrome patients with PCI

0.9 mg/kg loading dose + 1.8 mg/kg/h for 4 h;

1.2 mg/kg loading dose + 2.3 mg/kg/h for 4 h;

0.6 mg/kg loading dose + 1.2 mg/kg/h for 4 h

IV

Phase II

Risuteganib

NCT02153476;

NCT02348918;

NCT02435862;

NCT03626636;

Allegro Ophthalmics

Peptide

2014-06-03

2015-01-28

2015-05-06

2018-08-13

αvβ3;αvβ5;α2β1;

α5β1

Symptomatic focal vitreomacular adhesion;

diabetic macular edema;

non-proliferative diabetic retinopathy;

non-exudative macular degeneration

Symptomatic Focal Vitreomacular Adhesion: 2.0 mg;

Diabetic Macular Edema: 0.5 mg, 1.0 mg, 2.0 mg or 3.0 mg;

Non-Proliferative Diabetic Retinopathy: 1.0 mg, 2.0 mg or 3.0 mg;

Non-Exudative Macular Degeneration: 1.0 mg

injected intravitreally

Phase II

Antiangiotide

CTR20150368;

CTR20200847;

Inner Mongolia Tianqi Mongolian Medicine Group Co., Ltd.;

China Pharmaceutical University;

Peptide

2015-07-20

2020-08-28

αvβ3

Solid tumors

7.5、15 、30 、45 、60 、75 mg/m² QD or twice weekly

IV

Phase I

CEND-1

NCT05042128;

NCT05052567;

NCT05121038;

CTR20212588;

Australasian GastroIntestinal Trials Group;

Qilu Pharmaceutical Co., Ltd;

Anup Kasi;

Cend Therapeutics, Inc.;

Peptide

2021-09-13

2021-09-22

2021-11-16

2021-10-22

αvβ5

Pancreatic ductal adenocarcinoma;

colon and appendiceal cancers;

3.2 mg/kg

IV

Phase II

Dentonin

NCT01925261;

NCT02837900;

Orthotrophix Inc

Peptide

2013-08-19

2016-07-20

Integrin

Patellar osteoarthritis involving both knees;

patello-femoral osteoarthritis involving both knees;

Patellar Osteoarthritis Involving Both Knees: 200 mg 4 times weekly;

Patello-Femoral Osteoarthritis Involving Both Knees: 20 mg/50 mg/100 mg/200 mg

Intra-articular Injections

Phase II

Valategrast Hydrochloride

NCT00048009;

NCT00048022;

Hoffmann-La Roche

Peptide

2002-10-25

2002-10-25

α4β1;

α4β7

Asthma

Not mentioned

not mentioned

Phase II

Pegylated recombinant human endostatin

NCT01527864

Protgen Ltd

Peptide

2012-02-07

α5β1

Non-small cell lung cancer

10 mg/m² QW

IV

Phase II

Ac-PHSCN-NH2

NCT00131651

Attenuon Llc

Peptide

2005-08-19

α5β1;αvβ3

Renal cell cancer

three times weekly by short (10 min) IV infusion at 1 of 3 dose levels (20, 100, and 600 mg).

IV

Phase II (terminated)

AXT-107

NCT04697758;

NCT04746963;

AsclepiX Therapeutics, Inc.

Peptide

2021-01-06

2021-02-10

αvβ3;α5β1

Diabetic macular edema;

neovascular age-related macular degeneration

0.1 mg, 0.25 mg, or 0.5 mg

Intravitreal injection

Phase I/II

JSM-6427

NCT00536016

Jerini Ophthalmic

Peptide

2007-09-27

α5β1;

αvβ6;

αvβ8

Age-related macular degeneration

1.5 mg/ml, 3 mg/ml, 7.5 mg/ml 15 mg/ml QW

intravitreal injections

Phase I

Pury Peptide

CTR20170691;

CTR20181547;

Shaanxi Mccoot Technology Co., Ltd.

Peptide

2017-07-26

2019-10-22

αIIbβ3

Acute coronary syndrome with PCI

360ug/kg bolus + 5ug/kg/min IV for 6 h;

400ug/kg bolus + 7.5ug/kg/min IV for 6 h;

400ug/kg bolus + 10ug/kg/min IV for 6 h;

400ug/kg bolus + 13ug/kg/min IV for 6 h;

400ug/kg bolus + 16ug/kg/min IV for 6 h;

400ug/kg bolus + 20ug/kg/min IV for 6 h

IV

Phase I

PTG-100

NCT02895100

Protagonist Therapeutics

Peptide

2016-09-09

α4β7

Ulcerative colitis

150, 300 or 900 mg tid

Oral

Phase II

99mTc-3PRGD2

CTR20191465;

NCT04233476;

Peking University; Foshan Ridio Pharmaceutical Co. Ltd.; Institute of Biophysics, Chinese Academy of Sciences;

RDO Pharm.;

Imaging agent

2019-07-30

2020-01-18

αvβ3

Diagnosis for the lymph node metastasis in lung tumors

0.3 mCi/kg

IV

Phase III

Alfatide[18 F]

CTR20213024

Jiangsu Shimeikang Pharmaceutical Co., Ltd.;

Taizhou Qirui Pharmaceutical Technology Co., Ltd.;

Imaging agent

2021-12-10

αvβ3

Diagnosis for the lymph node metastasis in non-small-cell lung carcinoma

no more than 10 mL within 90 s, (0.1~0.15) ±0.015 mCi/kg

IV

Phase III

18F-FPPRGD2

NCT01806675;

NCT02995642;

Stanford University

Imaging agent

2013-03-07

2016-12-16

αvβ3

Cancer;

vascular inflammation

10 mCi

IV

Phase II

99mTc-rBitistatin

NCT00808626

Temple University

Imaging agent

2008-12-16

αIIbβ3

Venous thrombosis

10 mCi, 0.1 ug/kg

IV

Phase II (terminated)

Flotegatide-F18

NCT00988936;

NCT01602471;

NCT02325349;

Siemens Molecular Imaging

Imaging agent

2009-10-02

2012-05-21

2014-12-25

αvβ3

Metastatic breast cancer/metastatic colon/rectum cancer/non-squamous non-small cell lung cancer;

lung or head and neck cancers;

lymphoma;

carotid artery stenosis

Lung or Head and Neck Cancers: 2-4MBq/kg

IV

Phase II (terminated)

AH111585 (18 F)

NCT00918281

GE Healthcare

Imaging agent

2009-06-11

αvβ3;

αvβ5

Solid tumors

Not mentioned

IV

Phase II

(68)Ga-RGD

NCT05275699

Peking Union Medical College Hospital

Imaging agent

2022-03-11

αvβ3

Keloid

111 MBq

IV

Phase I

[68Ga]-FF58

NCT04712721

Novartis Pharmaceuticals

Imaging agent

2021-01-15

αvβ3;αvβ5

Solid tumors

3 MBq/Kg (+/- 10%)). no lower than 150 MBq or higher than 250 MBq

IV

Phase I

68Ga-NOTA-3PTATE-RGD

NCT02817945

Peking Union Medical College Hospital

Imaging agent

2016-06-29

αvβ3

Lung cancer;

neuroendocrine neoplasm

111-185 MBq

IV

Phase I

68Ga-NOTA-BBN-RGD

NCT02747290;

NCT02749019;

Peking Union Medical College Hospital

Imaging agent

2016-04-21

2016-04-22

αvβ3

Prostate cancer patients;

Breast cancer patients

111-148 MBq

IV

Phase I

68Ga-BNOTA-PRGD2

NCT01527058;

NCT01542073;

NCT01656785;

NCT01801371;

NCT01940926;

NCT02511197;

Peking Union Medical College Hospital

Imaging agent

2012-02-06

2012-03-01

2012-08-03

2013-02-28

2013-09-12

2015-07-29

αvβ3

Lung injury and pulmonary fibrosis;

glioma;

stroke;

lung cancer;

myocardial infarction;

rheumatoid arthritis

111 MBq (≤40 µg BNOTA-PRGD2)

IV

Phase I

Ga-68 NODAGA-RGD

NCT02666547

University of Lausanne Hospitals

Imaging agent

2016-01-28

αvβ3

Pathological angiogenesis

200 MBq

IV

Phase I

[18F]FP-R01-MG-F2

NCT02683824;

NCT03183570;

Stanford University

Imaging agent

2016-02-17

2017-06-12

αvβ6

Idiopathic pulmonary fibrosis;

primary sclerosing cholangitis;

Covid-19 pneumonia;

pancreatic cancer

7 mCi (range 6-9 mCi)

IV

Phase I

[18F]αvβ6- BP

NCT03164486

Julie L. Sutcliffe, Ph.D

Imaging agent

2017-05-23

αvβ6

Multiple cancers

up to 10 mCi

IV

Early phase I

99mTc- RWY

NCT04289532

Peking University

Imaging agent

2020-02-28

α6

Breast cancer

11.1 MBq/kg

IV

Early phase I

[18F]FBA- A20FMDV2

NCT04285996

Queen Mary University of London

Imaging agent

2020-02-26

αvβ6

Cancer

Not mentioned

Not mentioned

N/A

Zalunfiban

NCT04825743

Celecor Therapeutics

Small molecule

2021-04-01

αIIbβ3

ST-elevation myocardial infarction

0.11 mg/kg;

0.13 mg/kg

SC

Phase III

Firategrast

NCT00097331;

NCT00101946;

NCT00395317;

NCT00469378;

GlaxoSmithKline

Small molecule

2004-11-23

2005-01-19

2006-11-02

2007-05-04

α4β1

Multiple sclerosis;

Crohn’s disease

Multiple Sclerosis: 900 (females) or 1200 (males) mg bid

oral

Phase II

MORF-057

NCT05291689

Morphic Therapeutic

Small molecule

2022-03-23

α4β7

Ulcerative colitis

Not mentioned

Oral

Phase II

TRK-170

NCT01345799

Toray Industries, Inc

Small molecule

2011-05-02

α4β7

Crohn’s disease

Not mentioned

Not mentioned

Phase II

AJM-347

NCT03133468

EA Pharma Co., Ltd.

Small molecule

2017-04-28

α4β7

Unknown

Not mentioned

Oral

Phase I

PN-10943

NCT04504383

Protagonist Therapeutics

Small molecule

2020-08-07

α4β7

Ulcerative colitis

150 mg /450 mg BID

Oral

Phase II

E-7820

NCT00309179;

NCT01133990;

NCT01347645;

NCT05024994;

Eisai Inc.

Small molecule

2006-03-31

2010-05-31

2011-05-04

2021-08-27

α2

Bone marrow cancers;

colorectal cancer; rectal

cancer;

solid tumors

Myeloid: 100 mg QD;

Colon or Rectal Cancer: 40 mg/day, 70 mg/day, and 100 mg/day

Oral

Phase II

AXR-159

NCT03598699

Axerovision

Small molecule

2018-07-09

α4

Dry eye disease

Not mentioned

Topical

Phase II

VVN-001

NCT04556838;

CTR20211530;

VivaVision Biotech, Inc

Small molecule

2020-09-21

2021-07-01

LFA-1A

Dry eye disease

1% or 5% solution 1 drop in each eye every 12 h

Topical

Phase II

HYD-PEP-06

CTR20220769

Jilin Hayi University Pharmaceutical Co., Ltd.

Small molecule

2022-04-14

Pan-αv

Colorectal cancer

3.75 mg/kg QD for 14 days

IV

Phase II

GB-1275

NCT04060342

Gb006 Inc

Small molecule

2019-08-19

Integrin

Solid tumors

Not mentioned

Oral

Phase II

BIRT-2584-XX

NCT00333411

Boehringer Ingelheim Gmbh

Small molecule

2006-06-05

Integrin α

Psoriasis

100, 300 and 500 mg QD

Oral

Phase II

Milategrast

NCT03018054

EA Pharma Co., Ltd.

Small molecule

2017-01-11

Integrin

Ulcerative colitis

30 mg or 60 mg QD after breakfast

Oral

Phase II

MK-0429

NCT00533650

Merck Sharp; Dohme LLC;

Small molecule

2007-09-21

Pan-αv

PostMenopausal osteoporosis

Not mentioned

Not mentioned

Phase II

SF-0166

NCT02914613;

NCT02914639;

OcuTerra Therapeutics, Inc.

Small molecule

2016-09-26

2016-09-26

αvβ3;αvβ6;αvβ8

Age-related macular degeneration;

diabetic macular edema

5% solution twice a day

Topical

Phase II

AS-101

NCT00418249;

NCT00788424;

NCT00927212;

NCT00926354;

NCT01010373;

NCT01555112;

NCT01943630;

NCT03216538;

Biomas;

Rabin Medical Center;

Small molecule

2007-01-04

2008-11-11

2009-06-24

2009-06-23

2009-11-10

2012-03-15

2013-09-17

2017-07-13

α4β1;αvβ3

Age-related macular degeneration;

atopic dermatitis;

chemotherapy-induced thrombocytopenia;

HIV;

psoriasis;

myelodysplastic syndrome;

acute myeloid leukemia;

external genital warts;

female androgenetic alopecia

External Genital Wart: 15% gel QD;

MDS&AML: 3 mg/m² three times per week;

AMD: 1% oral solution 0.4 ml QD;

Psoriasis: 4% AS-101 Cream on the psoriatic lesions BID;

Atopic Dermatitis: 2% /4% ointment, topical application bid;

Chemotherapy induced thrombocytopenia: 3 mg/m² twice a week;

Female Androgenetic Alopecia: Topical use

Topical/ IV/ Oral

Phase II (terminated)

zaurategrast

NCT00484536;

NCT00726648;

UCB Pharma

Small molecule

2007-06-11

2008-08-01

α4β1

Multiple sclerosis

1000 mg QD for 4 weeks;

100 mg bid for 4 weeks;

500 mg bid for 4 weeks;

1000 mg bid for 4 weeks

Oral

Phase II (terminated)

THR-687

NCT05063734

Oxurion

Small molecule

2021-10-01

pan-αv;

α5β1

Diabetic macular edema

2.5 mg

intravitreal injections

Phase II (terminated)

RO-0506997

NCT00104143

Hoffmann-La Roche

Small molecule

2005-02-24

α4

Multiple sclerosis

20 mg, 80 mg or 300 mg, bid

Oral

Phase II (terminated)

BMS-587101

NCT00162253

Bristol-Myers Squibb

Small molecule

2005-09-13

αLβ2

Psoriasis

Not mentioned

Not mentioned

Phase II (terminated)

PLN-74809

NCT04072315;

NCT04396756;

NCT04480840;

NCT04565249;

Pliant Therapeutics

Small molecule

2019-08-28

2020-05-21

2020-07-21

2020-09-25

αvβ1;αvβ6

Primary sclerosing cholangitis;

idiopathic pulmonary fibrosis;

acute respiratory distress syndrome;

SARS-CoV-2;

Primary Sclerosing Cholangitis:40 mg, 80 mg or 160 mg

Oral

Phase II

LLP2A alendronate

NCT03197623

Nancy E. Lane, MD

Small molecule

2017-06-23

α4β1

Osteopenia secondary to glucocorticoids

50, 150, 400, 750 or 1200 μg/kg

IV

Phase I

GLPG-0187

NCT00928343;

NCT01313598;

NCT01580644;

Galapagos NV

Small molecule

2009-06-25

2011-03-14

2012-04-19

pan-αv;

α5β1;

Solid tumors

Not mentioned

IV/Oral/SC

Phase I

7HP-349

NCT04508179

7 Hills Pharma LLC

Small molecule

2020-08-11

αLβ2;α4β1;

Solid tumor

Not mentioned

Oral

Phase I

HYC-11395

CTR20182266

Hefei Heyuan Pharmaceutical Co., Ltd.;

Nanjing Heqi Pharmaceutical Technology Co., Ltd.;

Small molecule

2018-11-28

αIIbβ3

Acute coronary syndrome and thrombotic cardiovascular events

1 μg/kg

IV

Phase I

Lefradafiban

NCT02264106;

NCT02264119;

NCT02265289;

Boehringer Ingelheim Gmbh

Small molecule

2014-10-15

2014-10-15

2014-10-15

αIIbβ3

Thrombosis

30 mg Tid

Oral

Phase I

BIIB-107

NCT04593121

Biogen

Small molecule

2020-10-19

α4

Multiple sclerosis;

Not mentioned

SC

Phase I

IDL-2965

NCT03949530

Indalo Therapeutics

Small molecule

2019-05-14

pan-αv

Idiopathic pulmonary fibrosis;

nonalcoholic steatohepatitis

Not mentioned

Oral

Phase I

Pagantangentide

CTR20210520

Jiangsu aodexin Bio-pharmaceutical Technology Co., Ltd.;

China Pharmaceutical University;

Small molecule

2021-04-01

αvβ3

Rheumatoid arthritis

0.2 mg~4 mg

SC

Phase I

ELND-002

NCT01144351;

NCT01318421;

Elan Pharmaceuticals

Small molecule

2010-06-15

2011-03-18

α4

Multiple sclerosis

Not mentioned

SC

Phase I (terminated)

GSK-3008348

NCT02612051;

NCT03069989;

GlaxoSmithKline

Small molecule

2015-11-23

2017-03-03

αvβ6

Idiopathic pulmonary fibrosis;

1 to 3000 ug

Topical

Phase I (terminated)

OPC-415

NCT04649073

Otsuka Pharmaceutical Co., Ltd.

CAR T-cell therapy

2020-12-02

β7

Relapsed and/or refractory multiple myeloma

up to 1×10^7cells/kg On 2 days

IV

Phase II

Marnetegragene autotemcel

NCT03812263

Rocket Pharmaceuticals Inc

Cell- based therapy

2019-01-23

β2

Leukocyte adhesion deficiency-I

at least 2x10e6 total CD34 + cells/kg

IV

Phase II

BA 015 gene therapy

NCT01764009

Onxeo

Gene therapy

2013-01-09

α5β1;αvβ3

Melanoma

0.25 mg, 1 mg and 4 mg

IV

Phase II (terminated)

CAR- T therapy

NCT03778346

The Sixth Affiliated Hospital of Wenzhou Medical University

CAR T-cell therapy

2018-12-19

β7

Relapsed/refractory multiple myeloma

10^6-10^7/Kg

IV

Phase I

AG-73305

NCT05301751

Allgenesis Biotherapeutics Inc

Fusion protein

2022-03-31

Integrin

Diabetic macular edema

0.5 mg/ 1 mg/ 2 mg/ 3 mg

intravitreal

Phase II

Targeted NIF-hirulog hybrid

CXSL0600027

Chongqing Fujin bio-pharmaceutical Co., Ltd.

Fusion protein

2006-06-07

Integrin

Stroke

Not mentioned

Not mentioned

Phase I

ATL-1102

ACTRN12608000226303;

ACTRN12618000970246;

Antisense Therapeutics

Antisense oligonucleotide

2005-02-19

2018-08-28

α4

Duchenne muscular dystrophy; multiple sclerosis

Not mentioned

Not mentioned

Phase II

IMGN 388

NCT00721669

Immunogen Inc

Antibody drug conjugate

2008-07-24

αvβ3

Solid tumors

Not mentioned

IV

Phase I

SGN-B6A

NCT04389632

Seagen Inc.

Antibody drug conjugate

2020-05-15

β6

Solid tumors

Not mentioned

IV

Phase I

BGC-0222

CTR20221496

Gao Ruiyao Ye (Beijing) Technology Co., Ltd.

Peptide drug conjugate

2022-06-16

αvβ3

Solid tumors

Not mentioned

IV

Phase I

ProAgio

NCT05085548

ProDa BioTech, LLC

Novel proteins synthesized by computer simulation

2021-10-20

αvβ3

Pancreatic cancer;

solid tumor

3.2–36.8 mg/kg

IV

Phase I